U.S. House Rep. Jeff Hurd (R-Grand Junction) announced Thursday that Colorado’s 3rd Congressional District will be participating in the 2025 Congressional Art Competition.

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has reported its financial results for the year ending December ...

Most of us agree that those of us who work hard ought to make a decent living. We should be able to put food on the table, ...

ASEAN Markets: Since August 2024, XPOVIO ® has been successively approved in Malaysia, Thailand, and Indonesia, marking significant progress in Antengene's commercialization strategy across the APAC ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company ...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 ...

Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

I am a resident of CD3 in Montrose. I identify as DEIA. I am a mom, social worker, disabled, and a member of the Indivisible Montrose group. I am requesting that you hold an in-person town hall in ...